Effect of cachexia on bone turnover in cancer patients: a case-control study.
Bone turnover
CRP
Cachexia
Carboxy terminal telopeptide of collagen type I (CTX)
Hypoalbuminemia
Osteocalcin (Ocn)
Procollagen type I N-terminal propeptide (PINP)
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
28 Jun 2021
28 Jun 2021
Historique:
received:
20
04
2021
accepted:
11
06
2021
entrez:
29
6
2021
pubmed:
30
6
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Increased bone turnover is frequently observed in advanced cancer and predominantly related to bone metastases or therapy. Cachexia represents an important cause of morbidity and mortality in cancer patients. Key features are weight loss, muscle wasting and chronic inflammation, which induce profound metabolic changes in several organs, including the bone. However, whether cachexia contributes to abnormal bone metabolism in cancer patients is unknown. Aim of the present study was to determine the potential correlation of bone turnover markers with body composition and laboratory parameters in treatment-naïve cancer patients. In this cross-sectional study we measured the levels of carboxy terminal telopeptide of collagen (CTX), an indicator of bone resorption, as well as osteocalcin (Ocn) and procollagen type I N-terminal propeptide (PINP), indicators of bone formation, in 52 cancer patients and correlated with body composition and laboratory parameters. Univariate and multivariate logistic analysis were performed to identify determinants of negative bone remodeling balance, estimated by CTX/Ocn and CTX/PINP ratio. Based on weight loss, body mass index and muscle mass, patients were divided into a cachectic (59.6%) and a control (40.4%) group. After correcting for the presence of bone metastases, our results showed a significant upregulation of CTX in cachectic patients compared to non-cachectic cancer patients (median 0.38 vs 0.27 ng/mL, p < 0.05), with no difference in Ocn and PINP levels (mean 14 vs. 16 ng/ml, p = 0.2 and median 32 vs. 26 μg/L, p = 0.5, respectively). In addition, the CTX/Ocn and the CTX/PINP ratio were indicative of bone resorption in 68% and 60% of cachexia patients, respectively (vs. 20% and 31% in the control group, p = 0.002 and p = 0.06). The main determinants of the unbalanced bone turnover were hypoalbuminemia for the CTX/Ocn ratio (OR 19.8, p < 0.01) and high CRP for the CTX/PINP ratio (OR 5.3, p < 0.01) in the multivariate regression analysis. CTX is substantially higher in cachectic patients compared to non-cachectic oncological patients and hypoalbuminemia as well as elevated CRP concentrations are independent predictors of a negative bone remodeling balance in cancer patients. These results strongly indicate that cachexia correlates with exacerbated bone turnover in cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Increased bone turnover is frequently observed in advanced cancer and predominantly related to bone metastases or therapy. Cachexia represents an important cause of morbidity and mortality in cancer patients. Key features are weight loss, muscle wasting and chronic inflammation, which induce profound metabolic changes in several organs, including the bone. However, whether cachexia contributes to abnormal bone metabolism in cancer patients is unknown. Aim of the present study was to determine the potential correlation of bone turnover markers with body composition and laboratory parameters in treatment-naïve cancer patients.
METHODS
METHODS
In this cross-sectional study we measured the levels of carboxy terminal telopeptide of collagen (CTX), an indicator of bone resorption, as well as osteocalcin (Ocn) and procollagen type I N-terminal propeptide (PINP), indicators of bone formation, in 52 cancer patients and correlated with body composition and laboratory parameters. Univariate and multivariate logistic analysis were performed to identify determinants of negative bone remodeling balance, estimated by CTX/Ocn and CTX/PINP ratio.
RESULTS
RESULTS
Based on weight loss, body mass index and muscle mass, patients were divided into a cachectic (59.6%) and a control (40.4%) group. After correcting for the presence of bone metastases, our results showed a significant upregulation of CTX in cachectic patients compared to non-cachectic cancer patients (median 0.38 vs 0.27 ng/mL, p < 0.05), with no difference in Ocn and PINP levels (mean 14 vs. 16 ng/ml, p = 0.2 and median 32 vs. 26 μg/L, p = 0.5, respectively). In addition, the CTX/Ocn and the CTX/PINP ratio were indicative of bone resorption in 68% and 60% of cachexia patients, respectively (vs. 20% and 31% in the control group, p = 0.002 and p = 0.06). The main determinants of the unbalanced bone turnover were hypoalbuminemia for the CTX/Ocn ratio (OR 19.8, p < 0.01) and high CRP for the CTX/PINP ratio (OR 5.3, p < 0.01) in the multivariate regression analysis.
CONCLUSIONS
CONCLUSIONS
CTX is substantially higher in cachectic patients compared to non-cachectic oncological patients and hypoalbuminemia as well as elevated CRP concentrations are independent predictors of a negative bone remodeling balance in cancer patients. These results strongly indicate that cachexia correlates with exacerbated bone turnover in cancer.
Identifiants
pubmed: 34182958
doi: 10.1186/s12885-021-08518-9
pii: 10.1186/s12885-021-08518-9
pmc: PMC8240310
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
744Références
Physiol Rep. 2013 Nov;1(6):e00144
pubmed: 24400146
J Electr Bioimpedance. 2018 Dec 31;9(1):96-105
pubmed: 33584925
Front Oncol. 2020 Aug 04;10:1262
pubmed: 32850383
Proc Nutr Soc. 2015 Nov;74(4):355-66
pubmed: 25851205
Int J Med Sci. 2018 Feb 1;15(4):323-338
pubmed: 29511368
J Osteoporos. 2012;2012:528790
pubmed: 22934235
Clin Cancer Res. 2010 Aug 15;16(16):4084-93
pubmed: 20643782
Urol Oncol. 2018 Dec;36(12):528.e7-528.e13
pubmed: 30446461
J Clin Oncol. 2011 Apr 20;29(12):1599-606
pubmed: 21422438
Nat Rev Endocrinol. 2018 Dec;15(1):9-20
pubmed: 30464312
J Clin Oncol. 2009 May 1;27(13):2151-6
pubmed: 19349547
Nature. 2014 Sep 4;513(7516):100-4
pubmed: 25043053
J Cachexia Sarcopenia Muscle. 2021 Feb;12(1):70-90
pubmed: 33350058
J Am Geriatr Soc. 2002 May;50(5):889-96
pubmed: 12028177
Eur J Clin Nutr. 2015 Dec;69(12):1290-7
pubmed: 26220573
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Br J Cancer. 2003 Sep 15;89(6):1028-30
pubmed: 12966420
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):507-509
pubmed: 27891294
Nutr Cancer. 2021;73(2):230-238
pubmed: 32270713
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
Osteoporos Sarcopenia. 2020 Dec;6(4):179-184
pubmed: 33426306
J Clin Endocrinol Metab. 2016 Jan;101(1):167-75
pubmed: 26600169
Endocrine. 2015 Nov;50(2):344-54
pubmed: 25636442
Nutrition. 2019 Jul - Aug;63-64:200-204
pubmed: 31029048
J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):685-700
pubmed: 30009406
Clin Nutr. 2004 Dec;23(6):1430-53
pubmed: 15556267
J Endocr Soc. 2018 May 21;2(7):574-588
pubmed: 29942922
Osteoporos Int. 2009 Jun;20(6):843-51
pubmed: 19190842
J Clin Endocrinol Metab. 1998 Jul;83(7):2266-74
pubmed: 9661593
J Clin Endocrinol Metab. 2013 May;98(5):2146-52
pubmed: 23553865
Clin Nutr. 2008 Dec;27(6):793-9
pubmed: 18718696
J Card Fail. 2010 Apr;16(4):301-7
pubmed: 20350696
Exp Oncol. 2018 Jun;40(2):136-139
pubmed: 29949526
BMC Cancer. 2017 Feb 14;17(1):130
pubmed: 28193264
J Clin Endocrinol Metab. 1982 Aug;55(2):219-27
pubmed: 7085851
J Bone Miner Res. 2020 Feb;35(2):368-381
pubmed: 31614017
Front Physiol. 2017 Jan 11;7:679
pubmed: 28123369
Obes Res Clin Pract. 2019 Jul - Aug;13(4):378-384
pubmed: 31006614
Ann Oncol. 2014 Sep;25 Suppl 3:iii124-37
pubmed: 24782453
J Biol Chem. 2010 Aug 13;285(33):25103-8
pubmed: 20501658
BMC Musculoskelet Disord. 2016 Jul 11;17:268
pubmed: 27401188
Osteoporos Int. 2019 Sep;30(9):1755-1765
pubmed: 31227885
Best Pract Res Clin Endocrinol Metab. 2011 Aug;25(4):585-91
pubmed: 21872800
Front Endocrinol (Lausanne). 2019 Nov 19;10:809
pubmed: 31803146
Clin Interv Aging. 2017 Jul 19;12:1131-1140
pubmed: 28769558
Respir Med. 2009 Aug;103(8):1143-51
pubmed: 19304474
Cancer Med. 2018 Aug;7(8):3695-3703
pubmed: 29971962
Clin Biochem Rev. 2005 Nov;26(4):97-122
pubmed: 16648882
Nat Rev Drug Discov. 2012 Mar 01;11(3):234-50
pubmed: 22378270